Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation

Marta Gil-Martínez^{1

2}, José Manuel Rodrigo-Muñoz^{1

2}, Clara Lorente-Sorolla¹, Zahara García de Castro¹, Pablo Mínguez^{3

4

5}, José Antonio Cañas^{1

2}, Marcela Valverde-Monge^{2

6}, Jaime Bernaola⁶, Erwin Javier Pinillos-Robles⁷, Diana Betancor^{2

6}, Mar Fernández-Nieto⁶, Joaquín Sastre^{2

6}, María Jesús Rodríguez-Nieto^{7

8}, Victoria Del Pozo^{1

2

9}

Affiliations

¹ Immunoallergy Laboratory, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
² CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
³ Department of Genetics, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
⁴ Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
⁵ Bioinformatics Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
⁶ Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
⁷ Pulmonology Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
⁸ Hospital Universitario General de Villalba, Madrid, Spain.
⁹ Universidad Autónoma de Madrid, Madrid, Spain.

Marta Gil-Martínez et al. Allergy. 2024 Sep.

. 2024 Sep;79(9):2551-2553.

doi: 10.1111/all.16190. Epub 2024 Jun 6.

¹ Immunoallergy Laboratory, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
² CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
³ Department of Genetics, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
⁴ Center for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
⁵ Bioinformatics Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain.
⁶ Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
⁷ Pulmonology Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
⁸ Hospital Universitario General de Villalba, Madrid, Spain.
⁹ Universidad Autónoma de Madrid, Madrid, Spain.

No abstract available

Keywords: basophils; benralizumab; immunology; severe eosinophilic asthma; treatment.

References

1. Sehmi R, Lim HF, Mukherjee M, et al. Benralizumab attenuates airway eosinophilia in prednisone‐dependent asthma. J Allergy Clin Immunol. 2018;141(4):1529‐1532.e8. doi:10.1016/J.JACI.2018.01.008
1. Kolbeck R, Kozhich A, Koike M, et al. MEDI‐563, a humanized anti‐IL‐5 receptor alpha mAb with enhanced antibody‐dependent cell‐mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344‐1353.e2. doi:10.1016/J.JACI.2010.04.004
1. Hassani M, Koenderman L. Immunological and hematological effects of IL‐5(Rα)‐targeted therapy: an overview. Allergy. 2018;73(10):1979‐1988. doi:10.1111/ALL.13451
1. Lorente‐Sorolla C, Bernaola J, Sánchez‐Mellado D, et al. Long‐term immune response accompanies clinical outcomes in severe asthmatics treated with anti‐IL‐5/IL‐5R biologics. Allergy. 2023;78(11):3027‐3031. doi:10.1111/ALL.15872
1. Francuzik W, Pažur K, Dalke M, Dölle‐Bierke S, Babina M, Worm M. Serological profiling reveals hsa‐miR‐451a as a possible biomarker of anaphylaxis. JCI Insight. 2022;7(7):e156669. doi:10.1172/JCI.INSIGHT.156669